The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | A Phase I trial of tagraxofusp combined with pomalidomide and dexamethasone in RRMM
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a Phase I trial (NCT02661022) of tagraxofusp combined with pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma (RRMM). Dr Richardson highlights the impressive results of the study, which showed a manageable safety profile and significant activity, suggesting that this approach may be valuable in salvaging patients in the event of relapse. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, this is a very interesting study. I mean, essentially what we were using here was the idea of a plasmacytoid dendritic cell targeting antibody therapy combined with pomalidomide and dexamethasone. So a novel, small Phase I experience. We published this in Hematologica, and essentially what we were describing was the impact of this novel, powerful antibody, SL401, which is now obviously fully approved for its use in plasmacytoid dendritic leukemia, reapplying it in myeloma with a rational design because we’d realized that these plasmacytoid dendritic cells are a key part of the microenvironmental and immunological milieu in relapsed/refractory myeloma...
Well, this is a very interesting study. I mean, essentially what we were using here was the idea of a plasmacytoid dendritic cell targeting antibody therapy combined with pomalidomide and dexamethasone. So a novel, small Phase I experience. We published this in Hematologica, and essentially what we were describing was the impact of this novel, powerful antibody, SL401, which is now obviously fully approved for its use in plasmacytoid dendritic leukemia, reapplying it in myeloma with a rational design because we’d realized that these plasmacytoid dendritic cells are a key part of the microenvironmental and immunological milieu in relapsed/refractory myeloma. So the idea was by using this particular antibody, combining it with pomalidomide and dexamethasone, could we see a response signal and potential clinical benefit as well as, of course, safety. Well, the good news is we definitely saw safety. The combination was a manageable combination. We did actually have a relatively intensive schedule for the SL401, which was now being refined and adapted and used in the approved setting differently. But with this particularly small trial, it was lovely to see not only that there was a manageable safety profile, but really impressive results in terms of activity. And I think as we look to the future, some of these strategies may make important sense in the settings of novel immune therapies, right? So as we think about patterns of relapse after CAR-T, we realize that there are plasmacytoid dendritic components to that process. There’s some very nice data from a number of investigators and laboratory settings to confirm that that is the case. So rationally, these types of approaches may be of value in the setting of modern immunotherapy to help salvage patients should relapse occur. So a small study, interesting, provocative hopefully, and hopefully will lead to further work in the field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
